Eom Pharmaceutical Holdings IncOTC Pink - Limited Information:IMUC
- LAST PRICE0.6200
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.6200
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IMUC |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Eom Pharmaceutical Holdings Inc | 70.2M | -14.3x | --- |
Tonix Pharmaceuticals Holding Corp | 70.0M | -0.2x | --- |
aTyr Pharma Inc | 71.1M | -1.5x | --- |
Miromatrix Medical Inc | 68.4M | -2.4x | --- |
Candel Therapeutics Inc | 72.2M | -6.0x | --- |
Spruce Biosciences Inc | 72.8M | -1.6x | --- |
Company Information
EOM Pharmaceutical Holdings, Inc., formerly ImmunoCellular Therapeutics, Ltd. is a clinical-stage pharmaceutical company. The Company is focused on the development of novel therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. The Company’s portfolio consists of two product candidates: EOM613 and EOM147. EOM613 is an investigational, dynamically dual-acting immunomodulator. EOM613 is a peptide-nucleic acid solution and, based on past clinical data, have both an anti-inflammatory and pro-inflammatory effect at the site of cytokine and chemokine overactivity, and a pro-inflammatory effect when needed. EOM 147 is an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of retinal diseases. EOM is designed to counteract with the severe inflammatory effects of viruses, such as a cytokine storm or hyperimmune response following infection with the novel coronavirus that cause COVID-19.
Contact Information
- Headquarters
- 30721 Russell Ranch Road, Suite 140WESTLAKE VILLAGE, CA, United States 91362
- Phone
- 818-264-2300
- Fax
- 302-655-5049
Executives
- Chairman of the Board, Chief Operating Officer
- Eli Goldberger
- President, Chief Executive Officer, Director
- Irach Taraporewala
- Chief Financial Officer, Treasurer
- Wayne Danson
- Chief Scientific Officer
- Shalom Hirschman
- Independent Director
- Frank Douglas
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $70.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 113.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.07 |
EPS | $-0.04 |
Book Value | $-0.01 |
P/E Ratio | -14.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
